SCHEMBL6531022

SCHEMBL6531022

O=C(O)c1ccn(Oc2ccccc2)c1-c1ccccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.43
KDM4E B2RXH2 6/20 0.41
KDM6B O15054 1/20 0.41
KDM4A O75164 1/20 0.41
KDM5C P41229 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
KDM3A Q9Y4C1 1/20 0.41
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA3 P34903 1/20 0.39
PIN1 Q13526 1/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
LMNA P02545 2/20 0.38
P4HTM Q9NXG6 2/20 0.38
NAPRT Q6XQN6 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16703426 0.89 GRM5 (0.40) DHODHKDM4EKDM6BKDM4AKDM5C
SCHEMBL10187775 0.87 HDAC6 (0.44) KDM4EKDM4AGABRG2GABRB3GABRA3
SCHEMBL19207174 0.69 KDM4E (0.48) DHODHKDM4EKDM6BKDM4AKDM5C
SCHEMBL28338537 0.68 KDM4E (0.53) DHODHKDM4EKDM6BKDM4AKDM5C
SCHEMBL1173966 0.66 KDM4E (0.52) DHODHKDM4EKDM6BKDM4AKDM5C
SCHEMBL17427074 0.66 KDM4E (0.56) DHODHKDM4EKDM6BKDM4AKDM5C
SCHEMBL30620596 0.66 KDM4E (0.52) DHODHKDM4EKDM6BKDM4AKDM5C
Dipyridyl SCHEMBL2792069 0.66 KDM4E (0.74) KDM4EKDM6BKDM4AKDM5CKDM4C
Dipyridyl SCHEMBL18601618 0.66 KDM4E (0.74) KDM4EKDM6BKDM4AKDM5CKDM4C
Dipyridyl SCHEMBL30976994 0.66 KDM4E (0.74) KDM4EKDM6BKDM4AKDM5CKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614234-B2 Compounds as tyrosine kinase modulators ALLERGAN, INC. (US) 2013-12-24 US disclosed
EP-2473501-A1 COMPOUNDS AS TYROSINE KINASE MODULATORS Allergan, Inc. (US) 2012-07-11 EP disclosed
US-20110053905-A1 COMPOUNDS AS TYROSINE KINASE MODULATORS ALLERGAN, INC. (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053905-A1 COMPOUNDS AS TYROSINE KINASE MODULATORS ABL1, ERBB2, LCK DHODH 2718/4885KDM4E 1810/4885KDM6B 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.